# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
-8-K
Wells Fargo analyst Brandon Couillard initiates coverage on Myriad Genetics (NASDAQ:MYGN) with a Overweight rating and annou...
Scotiabank analyst Sung Ji Nam maintains Myriad Genetics (NASDAQ:MYGN) with a Sector Outperform and raises the price target ...
Piper Sandler analyst John Peterson maintains Myriad Genetics (NASDAQ:MYGN) with a Neutral and raises the price target from ...
TD Cowen analyst Dan Brennan maintains Myriad Genetics (NASDAQ:MYGN) with a Hold and raises the price target from $28 to $30.
JP Morgan analyst Rachel Vatnsdal maintains Myriad Genetics (NASDAQ:MYGN) with a Underweight and raises the price target fro...